P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients.

5064Background: We tested whether tissue-based analysis of p53 and PTEN genomic status, measured predominantly in primary tumor samples, may be predictive for sensitivity to abiraterone and enzalut...